UBS/CALL/ELI LILLY & CO/850.001/0.01/20.12.24 | Real-time Bid/Ask 05:44:39 2024-05-28 am EDT | ||
| 0.66 CHF / 0.68 CHF | +1.52% |
|
| Current month | +29.41% | ||
| 1 month | +57.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 0.66 | +1.54% |
| 24-05-23 | 0.65 | +3.17% |
| 24-05-22 | 0.63 | -1.56% |
Delayed Quote Swiss Exchange
Last update May 24, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYH3U | |
| ISIN | CH1329487545 |
| Date issued | 2024-03-04 |
| Strike | 850 $ |
| Maturity | 2024-12-20 (207 Days) |
| Parity | 100 : 1 |
| Emission price | 0.61 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.7 CHF |
|---|---|
| Lowest since issue | 0.39 CHF |
| Spread | 0.02 CHF |
| Spread % | 2.90% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.37%
- Stock Market
- Warrants
- LLYH3U Warrant
